Organigram Holdings stock (CA68620P1018): valuation metrics in focus after April CUSIP change

Organigram Holdings shares on Nasdaq continue to trade actively after an April 2025 CUSIP change, with investors watching valuation metrics and short-interest trends in a challenging Canadian cannabis landscape.

Organigram Holdings shares continue to trade on Nasdaq under the ticker OGI after the company underwent a CUSIP change effective 04/02/2025, a technical corporate action that did not alter shareholders economic interest but updated the securities identification used in clearing systems, according to information cited by Robinhoods corporate actions tracker as of 04/02/2025.

The stock remains part of the Canadian cannabis sector with its primary listing in Canada and a cross-listing on Nasdaq in the United States, giving investors in both markets access to the name as the industry adapts to a maturing domestic market and shifting regulatory frameworks.

The stock traded on Nasdaq under the symbol OGI in late May 2026, with active daily volume, while Canadian cannabis peers also continued to reflect sector-wide volatility that has marked the group in recent years.

As of 05/15/2026, Organigram Global, which represents Organigram Holdings trading presence on Nasdaq, showed short interest of 4,957,608 shares, equal to 3.53% of the public float, highlighting that a segment of the market is positioned for further downside or hedging strategies in the stock.

This short interest figure marked a 26.9% increase compared with the previous report showing 3,906,709 shares sold short, underscoring how sentiment has turned more cautious over the month while the broader Canadian cannabis space continues to adjust to price compression and intense competition.

The days-to-cover ratio stood at 5.3 based on an average daily trading volume of 753,218 shares as of 05/15/2026, suggesting that it would take more than one trading week of average activity for short sellers to close out their positions, a metric closely watched by traders monitoring potential squeezes or changes in positioning.

In Canada, the companys home market, Organigram Holdings remains exposed to the challenges facing licensed producers, as the domestic recreational cannabis market has matured with slower growth, falling wholesale prices, and consolidation pressure among producers trying to achieve sustainable profitability.

Analysts and investors in both Canada and the United States have also been watching consumer trends, regulatory developments, and capital access conditions that influence how cannabis companies such as Organigram Holdings can fund cultivation capacity, product innovation, and international expansion beyond their home markets.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: OGI
• Sector/industry: Cannabis producer and consumer packaged goods
• Headquarters/country: Moncton, Canada
• Core markets: Canadian recreational cannabis with select international channels
• Key revenue drivers: Branded adult-use cannabis products, bulk wholesale sales, and emerging export volumes
• Home exchange/listing venue: Nasdaq (OGI)
• Trading currency: USD

Organigram Holdings: core business model

Organigram Holdings focuses on cultivating and processing cannabis to supply branded and private-label products for the Canadian adult-use market while also seeking incremental growth from international medical and export channels.

Recent corporate actions

On 04/02/2025, Organigram Holdings executed a CUSIP identifier change for its shares, as reflected in Robinhoods corporate actions tracker, a back-office adjustment that typically follows corporate reorganizations or administrative updates but does not on its own alter shareholder voting rights or ownership proportions.

Valuation metrics and multiples for Organigram Holdings

Valuation of Organigram Holdings on Nasdaq is shaped by the broader reset in Canadian cannabis equities, where producers have seen significant share-price declines over the past several years and now often trade on metrics that reflect ongoing operating losses, restructuring charges, and the need to conserve cash.

Peers such as Tilray Brands, which also operates in the cannabis and consumer packaged goods space, illustrate the compressed valuations in the sector, with Tilray noted at a market capitalization of about USD 664.4 million and a negative price-to-earnings ratio of -0.41 as of a recent Robinhood snapshot, indicating that the market continues to price in current losses and uncertain earnings visibility across the group.

In this context, investors assessing Organigram Holdings often look beyond traditional trailing earnings multiples and instead weigh enterprise value relative to sales, gross margin trends, and cash-burn trajectories when comparing it to Canadian cannabis peers that are pursuing similar strategies to streamline operations and pivot toward higher-margin product categories.

Conclusion

The latest data points for Organigram Holdings, including the April 2025 CUSIP change and the mid-May 2026 short-interest figures, show an actively traded Canadian cannabis stock that continues to attract both bullish and bearish positioning on Nasdaq.

With Canadian cannabis producers facing a tougher maturing market and peers trading on compressed earnings-based multiples, Organigram Holdings valuation is more often assessed through revenue, margin, and balance-sheet metrics than through traditional profitability ratios, placing a premium on execution in its core markets.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.